Treatment of recurrent hemoptysis in a child with cystic fibrosis by repeated bronchial artery embolizations and long-term tranexamic acid

Wong, L. T. K.; Lillquist, Yolanda; Culham, Gordon; Dejong, B; Davidson, A. G. F.

doi:10.1002/(sici)1099-0496(199610)22:4<275::aid-ppul8>3.0.co;2-l

Cited by 37 publications

(14 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The treatment of choice for massive, life-threatening hemoptysis is BAE. Less severe forms of bleeding respond well to conservative treatment, 20,21 intended to control pulmonary infections and correct coagulation defects. All the BAE procedures in the series we reviewed had a successful outcome (complete control of bleeding).…”

Section: Discussionmentioning

confidence: 99%

Bronchial Artery Embolization for the Management of Nonmassive Hemoptysis in Cystic Fibrosis

Antonelli

Midulla

Tancredi

et al. 2002

Chest

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Bronchial Artery Embolization for the Management of Nonmassive Hemoptysis in Cystic Fibrosis

Antonelli

Midulla

Tancredi

et al. 2002

Chest

View full text Add to dashboard Cite

“…A couple of case reports have demonstrated some success with the use of tranexamic acid (TXA), intravenously and orally, in the setting of major hemoptysis unsuccessfully treated with BAE. 93,94 In one of these cases, attempts to withdraw TXA resulted in recurrence of hemoptysis. 94 By inhibiting plasminogen activators, this medication interferes with fibrinolysis.…”

Section: Hemoptysismentioning

confidence: 99%

Intensive Care Management of the Patient With Cystic Fibrosis

Kremer

Zwerdling

Michelson

et al. 2008

J Intensive Care Med

View full text Add to dashboard Cite

Cystic fibrosis was previously thought to be a disease of childhood. With a better understanding of this condition along with improvements in therapy, patients with cystic fibrosis are now living well into adulthood. The aim of this article is to familiarize the intensive care unit physician with cystic fibrosis care, to discuss complications associated with cystic fibrosis specifically related to the intensive care unit, and to detail the current recommendations for the clinical management of the patient with cystic fibrosis. With advancing disease, the most severely affected organs are the lungs. Obstruction, infection, and inflammation contribute to the decline of pulmonary function, ultimately leading to death. Some patients may be eligible for lung transplantation, but choosing wisely will affect posttransplant survival. Because other organs are affected by the genetic defect and associated treatments, serious complications related to the liver, pancreas, intestines, and kidneys must be considered by the intensivist faced with a patient with cystic fibrosis. As practitioners, the fact that not all patients will survive and help our patients and families gracefully through the end-of-life process should be accepted.

show abstract

“…The evidence base supporting the use of tranexamic acid for treating haemoptysis in patients with CF is limited to single case reports. 6,7 Tranexamic acid is a lysine derivative that blocks the lysine binding sites on plasminogen, preventing the plasmin-tPA complex from binding to fibrin, thus inhibiting fibrinolysis. 8 Administration by IV and oral routes result in peak serum levels after one and three hours, respectively.…”

Section: Discussionmentioning

confidence: 99%